Biotechnology

GeoVax Labs

Roth MKM Analyst Maintains Buy Rating on GeoVax Labs, Price Target at $14.00

GeoVax Labs released FY2025 Q3 earnings on November 13 After-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3114 (forecast USD -0.265)

GeoVax Labs released FY2025 9 Months Earnings on November 13 After-Market EST, actual revenue USD 2.489 M, actual EPS USD -1.1092

GeoVax Labs to Release FY2025 Q3 Earnings on November 13 After-Market (EST), Forecast Revenue USD 0, EPS USD -0.265

Aschoff Provides Healthcare Industry Stock Analysis and Recommendations

GeoVax Labs released FY2025 Q2 earnings on July 28 After-Market EST, actual revenue USD 852.28K (forecast USD 533.33K), actual EPS USD -0.3496 (forecast USD -0.36)

GeoVax Labs released FY2025 Semi-Annual earnings on July 28 After-Market EST, actual revenue USD 2.489 M, actual EPS USD -0.7889

GeoVax Labs to Release FY2025 Q2 Earnings on July 28 After-Market EST, Forecast Revenue USD 533.33K, EPS USD -0.36

GeoVax Labs Conducts Public Offering of Approximately 9.2 Million Units

GeoVax Labs Announces Patent for Malaria Vaccine

GeoVax Responds to WHO Declaring Monkeypox a Global Health Emergency

GeoVax to present positive immune data of GEO-CM04S1 in CLL patients at EHA

GeoVax Highlights Broad Cross-Protective Immunity of Its Multi-Antigen COVID-19 Vaccine Candidate

D. Boral Capital Downgrades Geovax Labs' Price Target and Rating

GeoVax Terminates BARDA Contract and Reports Q1 Earnings

GeoVax Labs released FY2025 Q1 earnings on May 1 After-Market (EST), actual revenue USD 1.637 M (forecast USD 1.25 M), actual EPS USD -0.4481 (forecast USD -0.6575)

GeoVax Labs to release FY2025 Q1 earnings on May 1 After-Market EST, forecast revenue USD 1.25 M, EPS USD -0.6575

D. Boral Capital Adjusts Geovax Labs Rating

GeoVax Labs Halts COVID-19 Vaccine Trial

GeoVax Labs, Inc. CEO David A. Dodd Purchases 10,000 Shares at $1.08 Each, Increasing Holdings by 37.51%

Intelligent Bio Solutions

Anghami

ESH Acquisition

Northann

ESH ACQUISITION CORP COM USD0.0001 CL A (S/R 13/06/2028)

Sidus Space

RISING DRAGON ACQUISITION CORP COM USD0.0001 15/11/2028 (SUBS/RT)

Urgently

Oriental Rise

Vanda Pharma

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

GeoVax Labs(GOVX.US)